Gland Pharma and Neuland Partner for Sterile API Manufacturing

What Happened ?

Gland Pharma and Neuland Laboratories have announced a long-term strategic CDMO partnership for sterile API manufacturing. Under the partnership, Gland Pharma will establish a sterile manufacturing suite for APIs pertaining to microparticle depot products at its JNPC facility in Visakhapatnam. The facility will be constructed and operated to cGMP, USFDA, and EU standards. The suite will add approximately 1,400 kg of annual capacity.

key details

• Long-term strategic CDMO partnership between Gland Pharma and Neuland Laboratories.
• Gland to establish sterile manufacturing suite at JNPC facility, Visakhapatnam.
• Facility to be cGMP, USFDA, and EU compliant.
• Annual capacity addition: ~1,400 kg.
• Focus: APIs for microparticle depot products and other complex sterile APIs.
• Integrated CDMO solution: Development, scale-up, regulatory support, commercial manufacturing.
• Combines Neuland’s complex API development expertise with Gland’s sterile manufacturing capabilities.
• Partnership expands existing relationship between the two companies.

Note:

• The collaboration aims to enhance supply resilience globally by combining Neuland’s development and regulatory expertise with Gland Pharma’s manufacturing capabilities, serving both innovator and generic pharmaceutical companies.

Risk Analysis

Summary:

• While the partnership expands Gland’s sterile API capabilities, risks include project execution, regulatory compliance, and demand variability.

Key Risks:

• Execution of facility construction and commissioning within timelines.
• Regulatory compliance and approvals from USFDA and EU authorities.
• Demand variability for sterile APIs and microparticle depot products.
• Competition from other CDMO players in the sterile API space.
• Technology transfer and scale-up challenges.
• Integration of complementary capabilities between two organizations.

Worst Case:

• Delays in facility commissioning or regulatory approvals could impact revenue contribution from the partnership.

Risk Level: Low to Medium

Company Commentary

Management highlighted that:

• Mr. Srinivas Sadu, Executive Chairman, Gland Pharma Limited: “We are pleased to further strengthen our collaboration with Neuland through this strategic partnership. This investment expands our capabilities in sterile API manufacturing and supports increasing customer demand.”
• “By leveraging the complementary strengths of both organizations, we will provide a robust and scalable CDMO solution backed by world-class quality, compliance and manufacturing excellence. We believe this partnership creates a strong foundation for sustainable growth and long-term value creation for our customers and both organizations.”
• Mr. Saharsh Davuluri, CEO & MD, Neuland Laboratories Limited: “Demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies. Through this partnership with Gland Pharma, we are combining Neuland’s expertise in complex APIs with Gland’s proven sterile manufacturing capabilities to create a differentiated platform for global customers.”
• “Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their CDMO partners.”